Anika Therapeutics (AKP) Stock Price & Analysis
AKP Stock Chart & Stats
- Day’s Range
- EUR 18.20 - EUR 18.20
- 52-Week Range
- EUR 7.00 - EUR 18.20
- Previous Close
- EUR 18.20
- Volume
- 0
- Average Volume (3M)
- 4
- Market Cap
- EUR 250.21M
- Enterprise Value
- EUR 187.52M
- Total Cash (Recent Filing)
- EUR 38.41M
- Total Debt (Recent Filing)
- EUR 23.32M
- Price to Earnings (P/E)
- ―
- Beta
- 0.66
- Next Earnings
- Nov 06, 2026 (Est.)
- EPS Estimate
- 0.38
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Channel Growth
Broad-based revenue growth, including strong commercial and international performance, indicates improving demand across the portfolio rather than reliance on one isolated product. Sustained channel expansion can strengthen scale, support investment, and improve the company’s ability to compound sales over the next several quarters.
Margin And Operating Improvement
The sharp improvement in gross margin and adjusted EBITDA shows that manufacturing productivity, throughput gains, yields, and product mix are translating into stronger operating economics. If these improvements persist, they can provide a more durable earnings foundation and increase internal funding for growth initiatives.
Conservative Balance Sheet
A debt-free balance sheet with substantial cash gives Anika financial flexibility while it advances products, expands capacity, and manages regulatory requirements. This liquidity reduces financing pressure, improves resilience during periods of uneven orders, and allows management to fund opportunities without relying on additional borrowing.
Bears Say
Hyalofast FDA Uncertainty
The unresolved PMA review creates a structural commercialization risk for Hyalofast in the United States. Approval timing or an unfavorable outcome could delay market access, reduce expected portfolio contribution, and require the company to depend more heavily on existing products and international demand.
CINGAL Regulatory Investment Burden
CINGAL’s drug-combination classification increases the regulatory and operational work required before a potential NDA submission. Substantial CMC activities, manufacturing upgrades, and targeted investment may weigh on near-term resources, while delaying the product’s ability to become a larger growth contributor.
Persistent Loss-making Performance
Despite improved operating momentum, Anika remains loss-making and generates only thin free cash flow, with cash generation lower than the prior annual period. Persistent negative earnings limit internally funded growth and make the company more dependent on sustaining operational improvements before profitability becomes durable.
Anika Therapeutics News
AKP FAQ
What was Anika Therapeutics’s price range in the past 12 months?
What is Anika Therapeutics’s market cap?
When is Anika Therapeutics’s upcoming earnings report date?
How were Anika Therapeutics’s earnings last quarter?
Is Anika Therapeutics overvalued?
Does Anika Therapeutics pay dividends?
What is Anika Therapeutics’s EPS estimate?
How many shares outstanding does Anika Therapeutics have?
What happened to Anika Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Anika Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Anika Therapeutics Stock Smart Score
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Stephen D. Griffin
- Employees
- 235
- Website
- www.anika.com
- Address
- 32 Wiggins Avenue, Bedford, MA, 01730, US
Anika Therapeutics (AKP) Earnings & Revenues
AKP Company Deck
AKP Earnings Call
Earnings Call SentimentPositive
The call highlights clear commercial momentum (record international and commercial channel revenue), strong operational improvements (mid-60s gross margins, capacity expansions), and meaningful profitability gains (highest adjusted EBITDA since 2020) that supported upward guidance revisions. Key risks include FDA review uncertainty for Hyalofast, required CMC work for CINGAL, OEM revenue/order timing variability, modest U.S. pricing headwinds, and near-term cash conversion timing. Overall, positive execution and raised guidance outweigh the regulatory and timing headwinds.
View all DE:AKP earnings summariesAKP Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 4 |
| Technical Analysis | 4 | 1 | 4 |
| Moving Averages | 12 | 0 | 0 |